Merck (MRK) Profit After Tax (2009 - 2026)
Merck (MRK) posted quarterly Profit After Tax of -$4.2 billion for Q1 2026, down 183.48% YoY from $5.1 billion in Q1 2025, and down 243.15% sequentially from $3.0 billion in Q4 2025.
Merck (MRK) Profit After Tax (2009 - 2026) Analysis & Trends
Merck has disclosed Profit After Tax across 18 years of filings, most recently posting -$4.2 billion for Q1 2026.
- In Q1 2026, Profit After Tax fell 183.48% year-over-year to -$4.2 billion; the TTM figure through Mar 2026 stood at $8.9 billion (down 48.74% YoY), while the FY2025 annual figure was $18.3 billion, up 6.7% from the prior year.
- Profit After Tax retreated to -$4.2 billion in Q1 2026, from $3.0 billion in the prior quarter.
- Over the last five years, Profit After Tax for MRK reached as high as $5.8 billion in Q3 2025 and fell as low as -$6.0 billion in Q2 2023.
- The 5-year median for Profit After Tax is $3.7 billion (2024), against an average of $2.7 billion.
- Annual changes were most pronounced in 2023 — Profit After Tax sank 251.5% — and 2024, when it surged 407.08%.
- A 5-year view of Profit After Tax shows it stood at $3.0 billion in 2022, then slumped by 140.24% to -$1.2 billion in 2023, then surged by 407.08% to $3.7 billion in 2024, then decreased by 20.55% to $3.0 billion in 2025, then slumped by 243.15% to -$4.2 billion in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered -$4.2 billion, $3.0 billion, and $5.8 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 7.40 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 5.24 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 697.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 3.08 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -4.24 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 1.82 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 2.02 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 2.71 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 319.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.24 Bn |
| Dec 31, 2025 | 2.96 Bn |
| Sep 30, 2025 | 5.79 Bn |
| Jun 30, 2025 | 4.43 Bn |
| Mar 31, 2025 | 5.08 Bn |
| Dec 31, 2024 | 3.73 Bn |
| Sep 30, 2024 | 3.16 Bn |
| Jun 30, 2024 | 5.46 Bn |
| Mar 31, 2024 | 4.76 Bn |
| Dec 31, 2023 | -1.21 Bn |
| Sep 30, 2023 | 4.75 Bn |
| Jun 30, 2023 | -5.98 Bn |
| Mar 31, 2023 | 2.82 Bn |
| Dec 31, 2022 | 3.02 Bn |
| Sep 30, 2022 | 3.25 Bn |
| Jun 30, 2022 | 3.94 Bn |
| Mar 31, 2022 | 4.31 Bn |
| Dec 31, 2021 | 3.05 Bn |
| Sep 30, 2021 | 4.57 Bn |
| Jun 30, 2021 | 1.55 Bn |